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Organotellurides are newly described redox-catalyst molecules with original pro-oxidative properties. We have investigated the
in vitro and in vivo antitumoral effects of the organotelluride catalyst LAB027 in a mouse model of colon cancer and determined
its proﬁle of toxicity in vivo. LAB027 inducedan overproduction of H2O2 by both human HT29 and murine CT26 colon cancer cell
linesinvitro.Thisoxidativestresswasassociatedwithadecreaseinproliferationandsurvivalratesofthetwocelllines.LAB027
triggered a caspase-independent, ROS-mediated cell death by necrosis associated with mitochondrial damages and autophagy.
LAB027 also synergized with the cytotoxic drug oxaliplatin to augment its cytostatic and cytotoxic effects on colon cancer cell
lines but not on normal ﬁbroblasts. The opposite effects of LAB027 on tumor and on non-transformed cells were linked to
differences inthe modulation ofreducedglutathionemetabolism between the twotypesofcells. InmicegraftedwithCT26tumor
cells, LAB027 alone decreased tumor growth compared with untreated mice, and synergized with oxaliplatin to further decrease
tumordevelopmentcomparedwithmicetreatedwithoxaliplatinalone.LAB027anorganotelluridecatalystcompoundsynergized
with oxaliplatin to prevent both in vitro and in vivo colon cancer cell proliferation while decreasing the in vivo toxicity of
oxaliplatin. No in vivo adverse effect of LAB027 was observed in this model.
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All living organisms need to maintain a healthy intracellular
redox balance in order to survive and to proliferate.
1 Reactive
oxygen species (ROS) are natural by-products of aerobic
metabolism whose production correlates with normal cell
proliferation through the activation of growth-related signaling
pathways.
2 Exposure to low levels of ROS can stimulate the
growth of many types of mammalian cells, whereas scaven-
gers of ROS suppress normal cell proliferation in human and
rodent ﬁbroblasts.
3,4 Furthermore, growth factors trigger the
productionofhydrogenperoxide(H2O2)thatleadstomitogen-
activated protein kinase activation and DNA synthesis, a
phenomenon inhibited by antioxidant molecules.
5,6 Several
observations suggest that ROS also participate in carcino-
genesis. First, ROS production is increased in cancer cells,
and an oxidative stress can induce DNA damages that lead to
genomic instability and possibly stimulate cancer progres-
sion.
7 Second, elevated ROS levels are responsible for the
activation of transcription factors, such as NF-kB and AP-1
during tumor progression.
8 Several studies have shown that
different types of cancer cells such as colon, liver, lung,
kidney, prostate and skin cancer cells
9–11 display a high
proliferation rate associated with an increased endogenous
production of ROS and a downregulation of their antioxidant
enzymatic systems.
On the other hand, ROS can also induce the apoptosis/
necrosis of cancer cells. Indeed, most anticancer drugs kill
theirtargetcells,atleastinpart,throughthegenerationofhigh
amounts of intracellular ROS that stimulate pro-apoptotic
signal molecules.
12,13 Several anticancer agents, such as 5-
ﬂuorouracil,
14 platinum,
9,12 arsenic trioxide,
15 paclitaxel,
16
and anthracyclines
17 increase the intra-cellular levels of ROS.
Tumor cells generate higher levels of ROS compared with
normal cells and are therefore more sensitive to the additional
oxidative stress caused by anticancer agents.
9,12,18
Cells also contain a variety of free radical scavenging
systems that protect them from the effects of drugs that
generate ROS. Catalase and glutathione peroxidase are
enzymes that detoxify H2O2. High levels of reduced
glutathione, the cofactor of glutathione peroxidase, have
been associated with the multidrug resistance phenotype in
tumor cells.
19 Therefore, compounds that target such
protective mechanisms could enhance the activity of antic-
anceragentsandreversethemultidrugresistancephenotype.
For example, buthionine sulfoximine (BSO), a glutathione
synthesis inhibitor, can increase the cytotoxicity of melphalan
by preventing glutathione peroxidase activity.
20 Conversely,
N-acetylcysteine protects normal cells from the cytotoxic
effects of anticancer drugs by preventing the elevation of
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9 SOD
enzymes can also affect tumor cell proliferation via their
effects on peroxide levels. Thus, the overexpression of SOD
in human cancer cell lines or the use of nonpeptidyl mimic of
SOD increases H2O2 production and reduces tumor
growth.
9,16,21,22
Killing cancer cells through the oxidative stress may require
compounds that generate ROS and, more appropriately,
catalysts that convert the intracellular ROS into a cocktail of
cytotoxic chemical species that selectively kills cancer
cells.
18,23 Compounds that contain quinones and tellurium
are cytotoxic at low concentrations.
24 The LAB027 compound
that associates a quinone core along with two tellurium atoms
can thus be considered as the prototype of pro-oxidative
tellurium compounds. However, LAB027 as well as the other
multifunctional redox catalysts synthesized so far have
always been tested alone and in vitro.
Colon cancer cells are highly sensitive to the oxidative
stress
18 and are currently treated by 5FU, oxaliplatin and
irinotecan, thatgenerate anintracellular stressin cancercells.
The capacity of organotelluride catalysts to generate an
intracellular oxidative burst alone and in combination with a
pro-oxidative cytotoxic drug, prompted us to test these
molecules against colon cancer in vitro and in vivo. Therefore,
we investigated the antitumoral activity of the organotelluride
catalyst LAB027 alone and in combination with oxaliplatin in
vitro and in vivo in an animal model of colon cancer. Because
of the therapeutic potential of this compound, an evaluation of
its proﬁle of toxicity proﬁle has also been performed.
Results
LAB027 exerts pro-oxidative effects in vitro. Incubation
of mouse CT26 and human HT29 colon cancer cell lines with
increasing amounts of LAB027, dose-dependently increased
the production of O2
K  (CT26: Po0.05 with 2mM LAB027;
HT29: Po0.05 with 1mM LAB027) (Figure 1). A dose-
dependent increase in the production of H2O2 was also
observed (CT26: Po0.05 with 2mM LAB027; HT29: Po0.05
with 2mM LAB027) (Figure 1). Incubation of NIH3T3
ﬁbroblasts with increasing amounts of LAB027 had no
effects on the production of O2
K  (P¼NS), but dose
dependently increased the production of H2O2 by 500%
(NIH3T3: Po0.05 with 1mM LAB027) (Figure 1). Incubation
of W138 ﬁbroblasts with increasing amounts of LAB027 had
no effects on the production of O2
K  (P¼NS), but dose-
dependently increased the production of H2O2 by 260%
(W138: Po0.05 with 1mM LAB027) (Figure 1).
LAB027 alters the activities of antioxidant enzymes
in vitro. Incubation of CT26 and HT29 cells with
increasing amounts of LAB027 did not signiﬁcantly alter
SOD, catalase and glutathione reductase activities (P¼NS
compared with untreated cells) (Supplementary Figure 2). By
contrast, incubation of NIH3T3 or W138 ﬁbroblasts with
increasing amounts of LAB027 dose-dependently increased
the production of SOD (Po0.001 for NIH3T3 and Po0.001
for W138 with 4mM LAB027) and glutathione reductase
activities (Po0.001 for NIH3T3 and Po0.001 for W138 with
4mM LAB027) versus untreated cells (Supplementary Figure 2)
but had no effect on catalase levels.
LAB027 exerts cytostatic and cytotoxic effects
in vitro. Incubation of CT26 or HT29 cells with increasing
amounts of LAB027 dose-dependently decreased their
proliferative rates and their viability (Figures 2a and b). At
1mM, LAB027 decreased CT26 and HT29 proliferation rates
by 54% and 57%, respectively (Po0.001 for CT26 and
Po0.001 for HT29), and decreased their viability by 31 and
27%, respectively (Po0.001 for CT26 and Po0.05 for
HT29). Incubation of NIH3T3 or W138 ﬁbroblasts with
increasing amounts of LAB027, dose-dependently
decreased their proliferation rates and their viability. At
Figure 1 Productionof hydrogenperoxide (a) andof superoxideanions (b)by CT26, HT29,NIH3T3and W138cellsincubatedwith increasingconcentrations of LAB027.
Results are the mean±S.E.M. of three experiments performed in triplicates
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Cell Death and Disease1mM LAB027 decreased NIH3T3 and W138 proliferation
rates by 28 and 25%, respectively (Po0.001 for NIH3T3 and
Po0.001 for W138), and decreased their viability by 20 and
17%, respectively (Po0.05 for NIH3T3 and Po0.05 for
W138) (Figures 2a and b). LAB027 was signiﬁcantly more
cytostatic and cytotoxic in CT26 and in HT29 tumor cells lines
compared with non-tumoral NIH3T3 and W138 ﬁbroblasts
(cytostatic effect of 1mM LAB027: CT26 versus NIH3T3,
Po0.001; CT26 versus W138, Po0.001; HT29 versus
NIH3T3, Po0.001; HT29 versus W138, Po0.001;
cytotoxic effect of 2mM LAB027: CT26 versus NIH3T3,
Po0.001; CT26 versus W138, Po0.001 ; HT29 versus
NIH3T3, Po0.001; HT29 versus W138, Po0.001). The
antiproliferative effect of 1mM LAB027 on CT26, HT29
NIH3T3 and W138 cells was signiﬁcantly abrogated in vitro
by 400mM N-acetylcysteine (Po0.05; Po0.02; Po0.05;
Po0.05, respectively). By contrast, the SOD mimic MnTBAP
that produces H2O2 through the dismutation of O2
K ,
signiﬁcantly increased the antiproliferative activities of 1mM
LAB027 on CT26 (Po0.05), on HT29 (Po0.02), on NIH3T3
(Po0.05) and on W138 (Po0.05). Incubation of 1mM
LAB027 with the gamma-glutamylcysteine synthetase
inhibitor BSO that depletes intracellular GSH, signiﬁcantly
augmented the cytotoxicity of LAB027 in all cell lines
(Po0.001). By contrast, blocking catalase by aminotriazol
or increasing its intracellular levels by incubation with
PEG-catalase had no effects on cell survival or proliferation
whatever the cell type considered (Figure 2c).
Cytotoxic pathways engaged by LAB027. To determine
the pathway through which LAB027 promotes tumor cell
death, we examined by western blot the cleavage of
caspase-3 and caspase-8 proteins 24h after incubation of
HT29 tumor cells with increasing amounts of LAB027.
Although the expression of cleaved caspase-8 fragments
was dose-dependently upregulated in HT29 cells treated with
LAB027, no caspase-3 cleavage was observed in LAB027-
treated HT29 cells at any concentration tested (Figure 3a).
Incubation of HT29, CT26 or NIH 3T3 cells with either
caspase-3-speciﬁc inhibitor Ac-DEVD-FMK, or with caspase-
8 inhibitor Z-IETD-FMK or with the broad-spectrum caspase
inhibitor Z-VAD-FMK along with LAB027 did not modify the
cytotoxic effects of LAB027 (Figure 3b), whereas the latter
two caspases inhibitors effectively inhibited caspase-8
cleavage at the concentration tested (not shown). Early
intracellular events that occur during cell death are
associated with mitochondrial changes mediated by
members of the Bcl-2 family of proteins, including
antiapoptotic Bcl-2, Bcl-xL and pro-apoptotic Bax, Bad
proteins. In addition, treatment of HT29 cells with LAB027
triggered an autophagic process (Figure 3) as demonstrated
by ATG8 induction and cleavage, and by autophagic
Figure 2 Proliferation rates (a) and cytotoxicity (b) of CT26, HT29, NIH3T3 and W138 cells incubated with various concentrations of LAB027. Results are the
mean±S.E.M. of three experiments performed in triplicates. Proliferation (c) of CT26, HT29, NIH3T3 and W138 cell lines following incubation with 1mM LAB027 alone, or
associated with either 400mM N-acetylcysteine, 400mM DL-buthionine-(S,R)-sulfoximine (BSO), 200mM 3-amino-1,2,4-triazole (AT), 50units/ml catalase PEG (CAT) or with
100mM MnTBAP. Cellular proliferation was mesured by thymidine incorporation. Error bars represent S.E.M.
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Cell Death and Diseasevacuolization as demonstrated by acridine orange staining.
To clarify the mode of cell death, LAB027-treated HT29 cells
were stained with PI and YOPRO-1. After 24-h incubation
with 4mM LAB027, 5%±3 HT29 were positive for YOPRO-1
alone and 33%±7 HT29 were positive for PI alone or with
YOPRO-1 showing a necrotic process (Figure 3d). A kinetic
analysis of the mode of cell death between 6 and 24h
indicated that LAB027 induces cell death mainly through a
necrotic process (Figure 3e).
LAB027 synergized with oxaliplatin to trigger ROS
production and exert cytostatic effects on colon
cancer cell lines in vitro. Co-incubation of CT26 or HT29
cells with 5 or 0.5mM oxaliplatin and increasing
concentrations of LAB027, augmented the production of
H2O2 up to 323% (CT26) or 1215% (HT29) at the highest
concentration of LAB027 tested. By contrast, co-incubation
of mouse NIH3T3 ﬁbroblasts with 5mM oxaliplatin and
LAB027 did not augment the production of H2O2 versus
oxaliplatin alone (Figure 4). Moreover, co-incubation of
CT26, HT29 or NIH3T3 cells with oxaliplatin (5mM with
CT26 cells and NIH3T3 cells; 0.5mM with HT29 cells) with
increasing concentrations of LAB027 did not augment the
production of O2
K  versus oxaliplatin alone (Figure 4).
Figure 3 Pro-apoptotic effects of LAB027 (a). HT29 cells were treated or not with increasing concentrations of LAB027 for 24h. Expressions of cleaved caspase-8, pro-
caspase-3 and cleaved caspase-3, Bax, Bad, Bcl-xL, Bcl-2 and ATG8 proteins were analyzed by western blot. Proliferation rates (b) of CT26, HT29 and NIH3T3 cells
incubated with various concentrations of LAB027 alone or associated with either 40mM DEVD-FMK (caspase-3 inhibitor) or 40mM IETD-FMK (caspase-8 inhibitor) 40mM
ZVAD-FMK (broad-spectrum caspase inhibitor). Results are means±S.E.M. of three independent experiments. (c) Immunoﬂuorescence microscopy of HT29 cells stained
withacridineorangeandtreatedfor24hornotwith4mMLAB027.Anincreasednumberofcellswithstainedacidicvesicularorganelles(orangeﬂuorescence)in4mMLAB027
treated cells was observed. (d) Fluorescence-activated cell sorting analysis of cell death. Apoptosis/necrosis was analyzed by ﬂow cytometry using the Membrane
Permeability/Dead Cell Apoptosis Kit with YO-PRO-1 and Propidium iodide on HT29 treated (right panel) or not (left panel) with 4mM LAB027 for 24h. Necrotic cells are PI
positiveandYO-PRO-1positiveornegative.Apoptoticcellsare PInegativeandYO-PRO-1positive.Viablecellsarenegativefor bothdyes.Onerepresentativeexperimentof
three is shown. (e) Kinetic apoptosis/necrosis evolution in HT29 cells treated with 4mM LAB027 alone or with oxaliplatin 0.5mM
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Cell Death and DiseaseIncubation of HT29 colon cancer cells with 1mM LAB027
along with 0.5mM oxaliplatin signiﬁcantly increased the
antiproliferative potential of LAB027 by 31% (Po0.05) and
the antiproliferative potential of oxaliplatin by 23% (Po0.05).
By contrast, incubation of mouse NIH3T3 ﬁbroblasts with
1mM LAB027 along with 5mM oxaliplatin did not signiﬁcantly
modify the antiproliferative potential of LAB027 (P¼0.68) or
of oxaliplatin (P¼0.85) administered alone (Figure 5). A
kinetic analysis of the mode of cell death induced by co-
incubation of LAB027 with oxaliplatin was performed on
HT29 cells. The percentages of necrotic cells among
apoptoticþnecrotic cells were 81%, 84% and 84% after 6,
12 and 24h incubation, respectively, with LAB027 alone
compared with 60, 80 and 83% after 6, 12 and 24h
incubation, respectively, with oxaliplatinþLAB027
(Figure 3e).
Imbalance of GSH metabolism in tumor cells. In normal
NIH3T3 cells, increasing the oxidative stress by incubation
with 4mM LAB027 augmented intracellular GSH levels by
311% (Figure 5). Adding 5mM oxaliplatin to LAB027, further
increased GSH synthesis by 80%. Interestingly, incubating
CT26 or HT29 colon cancer cells with LAB027 alone or in
association with oxaliplatin failed to increase GSH synthesis
(Figure 5). In order to determine whether this phenomenon
was linked to a differential effect of LAB027 on GSH efﬂux in
normal and tumor cells, we measured the GSH released from
CT26, HT29 or NIH3T3 upon incubation with increasing
concentrations of LAB027 alone or in association with
oxaliplatin. Increasing concentrations of LAB027
signiﬁcantly induced GSH release, but no difference was
observed between normal and tumor cells (Supplementary
Figure 3).
Co-incubation of oxaliplatin and LAB027 with the glu-
tathione reductase inhibitor BSO that depletes the cells in
reduced glutathione, signiﬁcantly increased the antiprolifera-
tive potential of oxaliplatinþLAB027 in all cell lines
(Po0.001). In addition, incubation with NAC, a precursor of
GSH signiﬁcantly increased cell proliferation (Po0.001 for
HT29 and CT26 and Po0.05 for 3T3). By contrast, blocking
catalase with aminotriazol or increasing its intracellular levels
with PEG-catalase had no effect on cell survival and
proliferation whatever the cell type considered (Figure 5).
Effect of LAB027 on the growth of CT26 tumor cells
implanted in mice treated with oxaliplatin. To determine
whether LAB027 could inhibit tumor growth in vivo,w e
treated mice bearing CT26 tumors with either oxaliplatin or
LAB027, or with the association of oxaliplatin and LAB027
(Figure 6a). Mice treated with oxaliplatin alone developed
signiﬁcantly smaller tumors than untreated mice (–58%,
Po0.001 versus untreated mice on day 27). LAB027 also
inhibited tumor growth when administered alone ( 25% on
day 27, Po0.05 versus untreated mice). Mice treated
simultaneously with LAB027 and oxaliplatin had
signiﬁcantly smaller tumors than untreated mice on day 27
( 75%, Po0.001). Furthermore, the administration of
LAB027 ampliﬁed the antitumor effect observed with
oxaliplatin alone ( 41% versus oxaliplatin-treated mice,
Po0.05 on day 27). In order to determine whether the
immune system has a role in the antitumoral effects induced
by LAB027 alone or in combination with oxaliplatin, we
performed the same experiment using immunodeﬁcient
SCID mice. In SCID mice implanted with CT26, LAB027
inhibited tumor growth when administered alone ( 24% at
day 27, Po0.05 versus untreated mice). SCID mice treated
simultaneously with LAB027 and oxaliplatin had signiﬁcantly
smaller tumors than untreated mice at day 27 ( 78%,
Po0.001). The administration of LAB027 ampliﬁed the
antitumor effect observed with oxaliplatin alone ( 56%
versus oxaliplatin-treated mice, Po0.05 at day 27).
In vivo effects of LAB027 on the toxicity of oxaliplatin
and on the susceptibility of mice to bacterial
Figure 4 Production of hydrogen peroxide (a) and superoxide anions (b) by oxaliplatin-treated CT26, HT29 and NIH3T3 cells incubated with increasing concentrations of
LAB027.Differences(delta)inH2O2production(a)andinO2
K production(b)betweenoxaliplatin-treatedcellsanduntreatedcellsareshown.Resultsarethemean±S.E.M.
of three experiments performed in triplicate
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Cell Death and Diseaseinfection. We next investigated the effects of LAB027 on
the toxicity of oxaliplatin in BALB/c mice. The toxicity on liver
was evaluated by measuring serum concentrations of ALAT,
LDH and alkaline phosphatases. Kidney function was
assessed on serum BUN and creatinin (Supplementary
Figure 4). None of these parameters were altered in the
serum of mice treated with oxaliplatin or LAB027 alone, or in
the serum of mice treated with both LAB027 and oxaliplatin.
After 14 days the ﬁrst injection of oxaliplatin, a signiﬁcant
decrease in the absolute numbers of peripheral leukocytes,
neutrophils and platelets was observed versus control mice
treated with PBS (Figure 6b). LAB027 alone had no
hematological toxicity compared with untreated control
mice. Furthermore, the administration of LAB027 in
association with oxaliplatin signiﬁcantly decreased the
hematological toxicity of oxaliplatin. Indeed, the counts of
peripheral leukocytes (P¼0.027), neutrophils (P¼0.008)
and platelets (P¼0.035) in the blood of mice treated with
LAB027 and oxaliplatin were higher than in the blood of mice
treated with oxaliplatin alone. Because bacterial infection is
the main complication of neutropenia, the susceptibility of
mice to intraperitoneal inoculation of E. coli was tested
following the administration of oxaliplatin alone or in
association with LAB027 (Figure 6c). In all, 40% of control
mice treated with PBS survived 28h after E. coli inoculation.
However, no animal treated with oxaliplatin before E. coli
inoculation, survived more than 22h following the bacterial
challenge. In contrast, 55% of mice treated with oxaliplatin
and LAB027 survived 28h following intraperitoneal
inoculation of E. coli (P¼0.044).
Discussion
This study provides pre-clinical evidence that the organotel-
luride catalyst LAB027, a prototypical member of family of the
‘sensor/effector’ multifunctional redox catalyst agents, is a
new candidate molecule to treat colon cancer either alone or
in combination with oxaliplatin.
Previous experiments have shown that ‘sensor/effector’
agentscanact ascytotoxic molecules invitro.
25 Theseagents
are catalytic molecules that recognize a particular intracellular
stateofcells–suchasanoxidativestress–andselectivelykill
the cells that are under this state. In our hands, tumor cells
display an elevated basal level of ROS that is ampliﬁed by
Figure 5 Proliferation(a)ofCT26,HT29andNIH3T3cellstreatedwithLAB027aloneorinassociationwith oxaliplatin.Errorbars representS.E.M.LAB027concentration
was 1mM for all the cells tested. Intracellular levels of reduced glutathione (b) in CT26 cells, HT29 cells and NIH3T3 cells treated with various concentrations of LAB027.
Resultsarethemean±S.E.M.ofthreeexperimentseachperformedintriplicate.Proliferation(c)ofCT26,HT29andNIH3T3celllinesfollowingincubationwith1mMLAB027
plus oxaliplatin alone, or associated with either 400mM N-acetylcysteine, 400mM DL-buthionine-[S,R]-sulfoximine (BSO), 200mM 3-amino-1,2,4-triazole (AT), 50units/ml
catalasePEG(CAT)orwith100mMMnTBAP.Oxaliplatinconcentrationwasrespectively5,0.5and5mMforCT26,HT29andNIH3T3cells.Cellularproliferationwasmesured
by thymidine incorporation. Error bars represent S.E.M.
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Cell Death and DiseaseLAB027 to generate a lethal oxidative burst. The most likely
explanation for this amplifying effect is an association of
oxygen radical and H2O2 formation at the quinone and
oxidation of cellular thiols catalyzed by tellurium in the
presence of H2O2. Those chemical reactions are likely to
increase the oxidative stress in tumor cells with a high initial
level of H2O2, and ultimately push those cells over a critical
‘life and death’ (redox) threshold.
24 This also accounts for the
differences of toxicity of the LAB027 compound in tumor and
normal cells. Moreover in tumor cells, the levels of antioxidant
enzyme activities are low and not modiﬁed by LAB027. In
normal cells, the basal levels of antioxidant enzyme activities
are higher and are still raised by LAB027, thus preventing cell
death.
9 The differences between normal and tumor cells in
terms of basal oxidative stress and antioxidant enzyme levels
have already been used to selectively kill tumor cells in vitro.
Thus,SODmimicsfavorthedismutation ofsuperoxideanions
overproduced by tumor cells, and consecutively raise the
productionofH2O2uptoacytotoxiclevelthatisnotreachedin
normalcellswithlow basallevelsofH2O2.
9,16Themechanism
ofactionofLAB027isdifferent;itinducesbyitself anoxidative
stress that is ampliﬁed by the pre-existing oxidative stress in
tumor cells. H2O2 and not O2
K  has a key role in the death
induced by LAB027, as N-acetylcysteine but not the SOD
mimic MnTBAP signiﬁcantly decreases LAB027 toxicity.
Incubation of LAB027 with the gamma-glutamylcysteine
synthetase inhibitor BSO that depletes the cells in reduced
glutathione signiﬁcantly increases the cytotoxicity of LAB027
in all cell lines. By contrast, blocking catalase with amino-
triazol or increasing its intracellular levels with PEG-catalase,
has no effects on cell survival and proliferation whatever the
cell type considered. These results indicate that H2O2-
mediated LAB027 toxicity is controlled by the glutathione
pathway rather than by the catalase pathway, as already
observed with several chemotherapeutic drugs.
The role of ROS in tumor cell death induced by LAB027 is
emphasized by the effects of the compound on the mitochon-
drialreleaseofpro-apoptoticmolecules.MembersoftheBcl-2
family control the permeability of the mitochondrial outer
membrane to various pro-apoptotic proteins.
26 In our hands,
LAB027 exerts its powerful cytotoxic effect by inhibiting the
expression of Bcl-2 and Bcl-xL, two antiapoptotic molecules,
and increasing the expression of Bax and Bad, two pro-
apoptotic molecules. This alteration in the mitochondrial
membrane composition leads to the mitochondrial collapse,
butisnotfollowedbycaspase-3cleavageasusuallyobserved
during apoptosis.
26 Those results are in line with the
ineffectiveness of caspase-3 inhibitors to abrogate LAB027-
induced cell death and with the necrotic mode of death
induced by LAB027 as demonstrated by YOPRO-1/PI
staining of LAB027-treated cells. ROS have been reported
to induce cell death by necrosis and/or apoptosis depending
on the rate of ROS production, the duration of the oxidative
burst and the cell type considered.
27 In our hands, LAB027
triggers a caspase-independent, ROS-mediated cell death by
necrosis. LAB027 also induces an autophagic process as
demonstrated by ATG-8 induction and cleavage, and by the
phenomenon of vacuolization. Indeed, H2O2 can trigger the
formation of autophagosomes through the oxidation of a
critical cysteine residue on HsAtg4A. The resulting inactiva-
tion of HsAtg4A leads to the accumulation of Atg8-PE on the
phagophore membrane and to the formation of autophago-
somes.
28 However, it is not clear whether this mechanism is
involved in cell death, or counteracts the toxic effects of
LAB027 and favours cell survival by removal of harmful
protein aggregates and damaged mitochondria, which are
sources of altered proteins.
29
The chemotherapeutic treatment of colon cancer usually
requires the use of several drugs. Oxaliplatin is one of the
most frequently used.
30,31 In our hands, the augmentation of
Figure 6 Tumorgrowthfollowingimplantationof2 10
6CT26cellsinBALB/cmice(a)orinSCIDmice(b).Miceweretreatedasdescribedinthe‘MaterialsandMethods
section’ (seven mice/group). Biological toxicity (c): leukocytes, neutrophils and platelets count in the blood of mice on day 14, following two i.v. injections of oxaliplatin
(10mg/kg) on days 1 and 7 and two injections of LAB027 (10mg/kg) on days1 and 7. Survival rate of mice (d) following intraperitoneal injectionof 10
7 E. coli in BALB/cmice.
Mice were treated as described in the ‘Material and Method section’ (10 mice/group)
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Cell Death and Diseasethe antiproliferative effects of oxaliplatin on colon cancer cells
when associated with LAB027, is linked to the increased
intracellular concentration of H2O2. However, a similar
increase in H2O2 concentration is observed in NIH3T3
ﬁbroblasts treated by oxaliplatin and LAB027, and no
antiproliferative effect is observed. This is explained by the
increase in GSH levels that occurs in normal 3T3 ﬁbroblasts
but not in colon cancer cells. Because of its role in H2O2
detoxiﬁcation, the glutathione pathway represents a major
component of cellular defense against cytotoxic drugs as
oxaliplatin These results are in agreement with the effect of
LAB027 on glutathione reductase levels, an enzyme that
restores the pool of reduced GSH and whose level is
increased in normal but not in tumor cells. The role of
glutathione reductase is also emphasized by the synergistic
effect of the gamma-glutamylcysteine synthetase inhibitor
BSO with LAB027 and oxaliplatin on tumor cells. The effect is
still more dramatic on normal cells.
Thus,ourdataconﬁrmthatoxaliplatinexertsitsanti-tumoral
effects at least partly through the induction of an oxidative
stress and emphasizes the role of reduced glutathione in the
control of oxaliplatin cytotoxicity.
32 In tumor cells, high levels
ofreducedglutathione,thecofactorofglutathioneperoxidase,
have been associated with a multidrug resistance pheno-
type.
19 Compounds that target such protective mechanisms
could enhance the activity of anticancer agents and reverse
the multidrug resistance phenotype. For example, BSO, an
inhibitor of glutathione synthesis, can increase the cytotoxicity
of melphalan by preventing glutathione peroxidase activity
and increasing H2O2 levels.
20 However, BSO depletes
glutathione in both normal and cancer cells, which increases
melphalan’s hematological toxicity and prevents any en-
hancement of the therapeutic index of this anticancer
agent.
33,34 Conversely, N-acetylcysteine protects normal
cells from the cytotoxic effects of anticancer drugs by
preventing the elevation of intracellular H2O2 through its
reductive properties,
9 but abrogates the effectiveness of
chemotherapeutic drugs. We have already observed that, as
LAB027, mangafodipir prevents the hematological toxicity of
oxaliplatin, but enhances its antitumoral activity against colon
cancer both in vitro and in vivo.
16 The differential cytotoxic
effects of mangafodipir on normal and cancer cells also result
from differences in the redox status of those cells. Mangafo-
dipir induces an overproduction of H2O2 through the dismuta-
tionofsuperoxideanions,butdecreasesthetoxicityofH2O2in
normal cells through its glutathione reductase-like activity.
Both mangafodipir and LAB027 increase the therapeutic
index of oxaliplatin in vitro and in vivo, prevent hematologic
toxicity and the death of animals injected with a lethal
concentration of bacteria. Moreover, arsenic trioxide, one of
the prototypical ‘sensor/effector’ chemotherapeutic agents,
exerts its antitumoral activity through the induction of an
oxidative burst without inducing leucopenia.
15
Only a small number of studies have previously explored
the antitumoral role of tellurium compounds. Only one
tellurium-based compound, AS101, has been tested so far.
AS101(ammoniumtrichloro(dioxoethylene-O,O0)tellurate),a
tellurium(IV)compound,isendowedwithantitumorproperties
in several murine models.
35,36 Phase I clinical trials on
patients with advanced cancer treated with AS101 have
shown an increased production and secretion of a variety of
cytokines,leadingtoacleardominanceofTh1responseswith
a concurrent decrease in Th2 responses.
37 The predomi-
nance of Th1 responses is related to the antitumor activity of
AS101. In addition, AS101, as a tellurium (IV) compound, can
interactwiththiolstoformaTe-Sbond.TheabilityofAS101to
interact with cysteine residue can alter protein functions,
38
increase intracellular ROS and favor the induction of
apoptosis.
39 However, all the activities of AS101 are
associated with little toxicity, and this drug is safe for clinical
applications.
40
The present study provides the ﬁrst pre-clinical evidence
that the organotelluride catalyst, LAB027 is a potential drug to
treat colon cancer either alone or in combination with
oxaliplatin through a mechanism that involves mainly necro-
sis. Tumor cell death is associated with the overproduction of
intracellular ROS but with no elevation of reduced glutathione
levels as observed in normal cells. This difference may
explain the limited kidney, liver and hematological toxicity of
this compound in vivo. Finally, this report shows for the ﬁrst
time that ‘sensor/effector’ pro-oxidative agents could repre-
sent effective and safe options to treat patients with colon
cancer.
Materials and Methods
Animals. BALB/c and BALB/c SCID female mice between 6 and 8 weeks of age
were used in all experiments (Harlan, Gannat, France). All mice were housed in
autoclaved cages with sterile food and water. Animals received humane care in
compliance with institutional guidelines.
LAB027 synthesis. The synthesis of LAB027 is described in detail in
Supplementary ﬁles (Supplementary data and Supplementary Figure 1).
Chemicals, cell lines and culture. All chemicals were from Sigma (Saint
Quentin Fallavier, France) except for oxaliplatin (Eloxatine, Sanoﬁ-Pharma, Paris,
France). CT26 (mouse colon carcinoma), HT29 (human colon carcinoma), NIH 3T3
(mouse ﬁbroblast) and W138 (human lung ﬁbroblast) were obtained from American
TypeCultureCollection(Manassas,VA,USA).AllcelllineswereculturedinDMEM/
glutamax-I supplemented with 10% heat-inactivated FCS and antibiotics (Life
Technologies, Cergy Pontoise, France). All cell lines were routinely tested for
Mycoplasma infection.
Cellular production of O2
K  and H2O2. Cells (2 10
4 cells/well) were
seededin 96-wellplates(Costar, Corning,Inc.,Corning,NY)andincubatedfor 48h
inculturemediumaloneoraddedwithvariousconcentrationsof LAB027aloneorin
combination with oxaliplatin. Levels of intracellular superoxide anion O2
K  and
H2O2 were assessed spectroﬂuorometrically (Packard Bioscience, Boston, MA,
USA) by oxidation of dihydroethidium (DHE) (Molecular Probes, Leiden, The
Netherlands) and of 20,70-dichlorodihydroﬂuorescein diacetate (H2DCFDA)
(Molecular Probes), respectively, as previously described.
16 The levels of O2
K 
or H2O2 were calculated in each sample as follows: ROS rate (arbitrary units/min/
10
6 cells)¼(ﬂuorescence intensity (arbitrary units) at T60 minutes ﬂuorescence
intensity (arbitrary units) at T0)/60min/number of viable cells as measured by the
crystal violet assay.
Determination of enzymatic activities. The SOD activity in tumor or
normal cells was evaluated by the method of Beauchamp and Fridovich
30 and
expressed as units/10
6 cells. The catalase activity in tumor or normal cells was
determined according to Aebi
41 and expressed as units/10
6 cells. The glutathione
reductase assay was performed by the method of Carlberg and Mannervik
42 and
expressedasnmol/min/10
6cells.LevelsofextracellularGSHweremeasuredbythe
method of Baker et al.
43 and expressed as nmol/10
6 cells.
In vitro cell proliferation and viability assays. CT26, HT29, NIH 3T3 or
W138 cells (2 10
4cells/well) were seeded into 96-well plates and incubated for
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oxaliplatin. Cell proliferation was determined by pulsing the cells with [
3H] thymidine
(1mCi/well) during the last 16h of culture. Cell viability was evaluated by the crystal
violet assay.
16 Results are expressed as percentages of viable cells compared with
untreated cells (that have 100% viability).
Levelsof intracellular andextracellular reducedglutathione. The
levels of intracellular glutathione were assessed spectroﬂuorometrically by
monochlorobimane staining.
44 Brieﬂy, tumor cells (2 10
4/well) or normal
NIH3T3 (2 10
4/well) were seeded in 96-well plates and incubated for 48h in
complete medium with LAB027 alone or in combination with oxaliplatin at
concentrations described in ﬁgure legends. Cells were washed once with PBS and
then incubated with 50mM monochlorobimane in PBS. The ﬂuorescence intensity
wasmeasuredafter 15min at 371C.Excitationandemissionwavelengthswere380
and 485nm, respectively. The intracellular glutathione level was expressed as
arbitrary units of ﬂuorescence intensity/number of adherent cells as measured by
the crystal violet assay. Extracellular reduced glutathione was assayed in culture
supernatants using the method of Baker et al.
43
Immunoblotting of cell lysates. HT29 cells were treated or not with 1, 2 or
4mM LAB027 for 24h then lysed in ice-cold RIPA.
9 Protein (50mg) extracts were
analyzed by immunoblotting after 10–15% SDS-PAGE using of rabbit polyclonal
anti-mouse pro- and active caspase-3 (1:1500, Abcam 47131, Paris, France),
rabbit polyclonal anti-mouse caspase-8, mouse polyclonal anti-mouse Bcl-2, Bcl-xL
and Bax primary antibodies (1:200, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), Bad primary antibody (1:100, Santa Cruz Biotechnology), ATG-8
primary antibody (1:500, Sigma-Aldrich, Saint-Quentin Fallavier, France) and
mouse monoclonal anti-b-actin (1:50000, Sigma). After washing, membranes
were incubated with a 1:1000 goat anti-rabbit or goat anti-mouse secondary
antibody (Sigma-Aldrich). The membranes were developed in Super Signal West
Pico Chemiluminescent Substrate (Pierce, CO, USA). Images of blots were
obtained using Fujiﬁlm LAS3000 digital imager analyzed with Fujiﬁlm Multi-Gauge
Imaging software (Fujiﬁlm, Tokyo, Japan).
Modulation of the catalase and glutathione reductase
pathways. HT29, CT26, NIH 3T3 or W138 cells (2 10
4cells/well) were pre-
incubated for 2h with either 400mmol/l N-acetyl cysteine (NAC), or with 50units/ml
PEG-catalase, or with 200mmol/l aminotriazol (ATZ, a catalase inhibitor) or with
400mmol/l L-buthionine-SR-sulfoximine (BSO, a gamma-glutamylcysteine
synthetase inhibitor). Those concentrations were chosen because they
signiﬁcantly modulated either reduced glutathione concentration (BSO, NAC) or
catalase activity (PEG-catalase, ATZ) (not shown). The cells were then incubated
with 1mM LAB027 alone or in combinationwith oxaliplatin for 48h. Cell proliferation
wasassayedby pulsingthecellswith [
3H] thymidine(1mCi/well)duringthelast16h
of culture.
Study of caspase inhibition. HT29 cells (2 10
4cells/well) were
pre-incubated for 2h with either 40mM caspase-3-speciﬁc inhibitor Ac-DEVD-
FMK or with 40mM caspase-8 inhibitor Z-IETD-FMK, or with the broad-spectrum
40mM caspase inhibitor Z-VAD-FMK. The cells were then incubated with LAB027
for 48h. Cell viability was evaluated by the crystal violet assay. Results are
expressed as percentages of viable cells compared with untreated cells (100%
viability).
Fluorescence-activated cell sorting analysis of cell
death. Apoptosis and necrosis were analyzed by the ﬂuorescence-activated
cell sorting (FACS) Canto II ﬂow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA), using the Membrane Permeability/Dead Cell Apoptosis Kit with YO-PRO-1
and Propidium iodide (PI) for Flow Cytometry (Invitrogen, Cergy Pontoise, France)
under the manufacturer’s recommendations. Brieﬂy, 5 10
5 HT29 cells were
incubated with 4mM LAB027 for a period of time indicated in the legends of ﬁgures.
After the incubation period, cells were collected and stained for 30min on ice with
1.5mM PI and 0.1mM YO-PRO-1. Cells were washed two times and analyzed by
ﬂow cytometry.
Acridine orange staining for autophagy detection. Acridine orange
(Sigma) staining was performed according to Kanzawa et al.
45 Brieﬂy, HT29 cells
were treated or not for 24h with 4mM LAB027. After the incubation period, cells
were washed twice with phosphate-buffered saline and stained with 1mM acridine
orange for 15min at 371C. Cells were washed and analyzed by ﬂuorescence
microscopy using 490-nm band-pass blue excitation ﬁlters and a 515-nm long-pass
barrier ﬁlter.
In vivo antitumor activity of LAB027. CT26 (2 10
6) cells were injected
subcutaneously into the back of BALB/c or BALB/c SCID mice. When the tumors
reached a mean size of 200–500mm
3, mice were randomized (day 10) in each
experimental and control groups depending on tumor size, in order to start the
treatment with a similar mean size in each group. One group of seven mice was
treated by intraperitonealoxaliplatin (10mg/kg/week)starting on day 10. One group
of seven mice was treated by intravenous LAB027 (10mg/kg/week) starting on day
10.OnegroupofsevenmicewastreatedwithintravenousLAB027(10mg/kg/week)
and intraperitoneal oxaliplatin (10mg/kg/week) starting on day 10. One control
group of seven mice was injected with PBS. Tumor size was measured with a
calliper rule every 2 days. Tumor volume was calculated as follows: TV
(mm
3)¼(L W
2)/2, where L is the longest and W the shortest radius of the
tumor in millimeters. Results were expressed as means of tumor volumes±S.E.M.
(n¼7 in each group).
In vivo analysis of blood, liver and kidney toxicity. Mice were injected
with PBS alone or intraperitoneal,oxaliplatin alone, or intravenous LAB027 alone or
intraperitoneal oxaliplatin in association with intravenous LAB027 at days 0 and 7.
Five mice were treated in each group. After 14 days of the ﬁrst injection, mice were
killed by cervical dislocation. Blood samples were then collected from each mouse.
Leukocytes, neutrophils and platelets were enumerated using a Malassez cell after
hypotonic red blood cell lysis. Liver enzymes ALAT, LDH, alkaline phosphatases,
BUN and creatinine were assayed using a multiparametric analyzer (Hitachi 747,
Roche Diagnostics, Meylan, France).
Susceptibilityof micetobacterialinfection. BALB/cfemalemicewere
injected with vehiclealone (PBS),or intraperitoneal oxaliplatin alone, or intravenous
LAB027 alone or intraperitoneal oxaliplatin and intravenous LAB027 days 0 and
seven.Fivemiceweretreatedineachgroup.After14daysoftheﬁrstinjection,mice
were injected i.p with a lethal dose of 10
7 E. coli on day 9. The survival rate of mice
was evaluated during 24h following E. coli injection. A total of 10 mice were treated
in each group in two independent experiments.
Statistical analysis. The statistical signiﬁcance of differences between
experimental treated groups and untreated controls was analyzed by Student’s
t-test for comparison of means. A level of Po0.05 was accepted as signiﬁcant.
*Po0.05; ***Po0.01 versus controls.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Acknowledgements. This research has been funded by a grant from the
EuropeanCommunity’sSeventhFrameworkProgram(FP7/2007-2013)undergrant
agreement no (215009). The authors thank Ms Agnes Colle for editing the
manuscript and Ms Marie Mianowski for reviewing the manuscript.
1. HalliwellB,GutteridgeJM.FreeRadicalsinBiologyandMedicine.OxfordUniversityPress:
UK, 2007.
2. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in
cancer. EMBO Rep 2002; 3: 420–425.
3. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation.
Free Radic Biol Med 1995; 18: 775–794.
4. Murrell GA, Francis MJ, Bromley L. Modulation of ﬁbroblast proliferation by oxygen free
radicals. Biochem J 1990; 265: 659–665.
5. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB et al. Epidermal growth factor
(EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine
phosphorylation. J Biol Chem 1997; 272: 217–221.
6. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2
for platelet-derived growth factor signal transduction. Science (New York, NY) 1995; 270:
296–299.
7. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the
multiple mutations in cancer. Mutat Res 2001; 477: 7–21.
8. Gupta A, Rosenberger SF, Bowden GT. Increased ROS levels contribute to elevated
transcription factor and MAP kinase activities in malignantly progressed mouse
keratinocyte cell lines. Carcinogenesis 1999; 20: 2063–2073.
Anticancer effects of a tellurium compound in mice
R Coriat et al
9
Cell Death and Disease9. LaurentA,Nicco C,ChereauC,GoulvestreC,AlexandreJ,AlvesAetal.Controlling tumor
growth by modulating endogenous production of reactive oxygen species. Cancer Res
2005; 65: 948–956.
10. Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and oxidative
stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 2008;
82: 273–299.
11. Oberley TD,Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol 1997;12:
525–535.
12. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically
transformed cells potentiates c-Jun N-terminal kinase and p38 mitogenactivated protein
kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001; 21: 6913–6926.
13. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants
and animals. Biochem Pharmacol 1999; 57: 231–245.
14. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP et al. Ferredoxin reductase
affectsp53-dependent,5-ﬂuorouracil-inducedapoptosisincolorectalcancercells.NatMed
2001; 7: 1111–1117.
15. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively
induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent
pathway. Blood 1999; 94: 2102–2111.
16. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F et al. Improvement of
thetherapeuticindexofanticancerdrugsbythesuperoxidedismutasemimicmangafodipir.
J Natl Cancer Inst 2006; 98: 236–244.
17. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I et al. p53-induced up-
regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis.
Cancer Res 2004; 64: 2350–2356.
18. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated
mechanisms: a radical therapeutic approach? Nat Rev 2009; 8: 579–591.
19. Hamaguchi K, Godwin AK, Yakushiji M, O’Dwyer PJ, Ozols RF, Hamilton TC. Cross-
resistance todiversedrugs isassociated withprimary cisplatinresistance inovariancancer
cell lines. Cancer Res 1993; 53: 5225–5232.
20. Skapek SX, Colvin OM, Grifﬁth OW, Elion GB, Bigner DD, Friedman HS. Enhanced
melphalan cytotoxicity following buthioninesulfoximine-mediated glutathione depletion in a
human medulloblastoma xenograft in athymic mice. Cancer Res 1988; 48: 2764–2767.
21. Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D et al. The role of
manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer
Res 2003; 63: 1297–1303.
22. Zhang Y, Zhao W, Zhang HJ, Domann FE, Oberley LW. Overexpression of copper zinc
superoxidedismutasesuppresseshumangliomacellgrowth.CancerRes2002;62:1205–1212.
23. HilemanEO,LiuJ,AlbitarM,KeatingMJ,HuangP.Intrinsicoxidativestressincancercells:
a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53:
209–219.
24. Mecklenburg S, Shaaban S, Ba LA, Burkholz T, Schneider T, Diesel B et al. Exploring
synthetic avenues for the effective synthesis of selenium- and tellurium-containing
multifunctional redox agents. Org Biomol Chem 2009; 7: 4753–4762.
25. Shabaan S, Ba LA, Abbas M, Burkholz T, Denkert A, Gohr A et al. Multicomponent
reactionsforthesynthesisofmultifunctionalagentswithactivityagainstcancercells.Chem
Commun (Camb, England) 2009; 40: 4702–4704.
26. Joza N, Kroemer G, Penninger JM. Genetic analysis of the mammalian cell death
machinery. Trends Genet 2002; 18: 142–149.
27. OrreniusS,GogvadzeV,Zhivotovsky B.Mitochondrial oxidativestress:implications forcell
death. Annu Rev Pharmacol Toxicol 2007; 47: 143–183.
28. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species
areessential for autophagy and speciﬁcally regulate the activity ofAtg4. EMBO J 2007;26:
1749–1760.
29. Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species
(ROS):implicationsfor cancer progression and treatment. Antioxid Redox Signal2009; 11:
777–790.
30. Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay
applicable to acrylamide gels. Anal Biochem 1971; 44: 276–287.
31. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F et al.
Oxaliplatin assingleagentin previously untreated colorectal carcinoma patients:a phase II
multicentric study. Ann Oncol 1998; 9: 105–108.
32. Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High
resistance to cisplatin in human ovarian cancer cell lines is associated with marked
increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992; 89: 3070–3074.
33. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB et al. Phase I
clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at
modulation of glutathione. J Clin Oncol 1994; 12: 194–205.
34. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C et al. Phase I
study of continuous-infusion L-SR-buthionine sulfoximine with intravenous melphalan.
J Natl Cancer Inst 1997; 89: 1789–1796.
35. Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J et al. The immunomodulator AS101
induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin
pathway. Biochem Pharmacol 2006; 72: 1423–1431.
36. Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben Ya’akov M et al. A new
immunomodulating compound (AS-101) with potential therapeutic application. Nature
1987; 330: 173–176.
37. Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G et al. Predominance of
TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl
Cancer Inst 1996; 88: 1276–1284.
38. Okun E, Dikshtein Y, Carmely A, Saida H, Frei G, Sela BA et al. The organotellurium
compound ammonium trichloro(dioxoethylene-o,o0)tellurate reacts with homocysteine to
form homocystine and decreases homocysteine levels in hyperhomocysteinemic mice.
FEBS J 2007; 274: 3159–3170.
39. Frei GM, Kremer M, Hanschmann KM, Krause S, Albeck M, Sredni B et al. Antitumour
effects in mycosis fungoides of the immunomodulatory, tellurium-based compound AS101.
Br J Dermatol 2008; 158: 578–586.
40. Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A et al. The protective role of the
immunomodulator AS101 against chemotherapy-induced alopecia studies on human and
animal models. Int J Cancer 1996; 65: 97–103.
41. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121–126.
42. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 1985; 113: 484–490.
43. Baker MA, Cerniglia GJ, Zaman A. Microtiter plate assay for the measurement of
glutathione and glutathione disulﬁde in large numbers of biological samples. Anal Biochem
1990; 190: 360–365.
44. Rice GC, Bump EA, Shrieve DC, Lee W, Kovacs M. Quantitative analysis of cellular
glutathione by ﬂow cytometry utilizing monochlorobimane: some applications to radiation
and drug resistance in vitro and in vivo. Cancer Res 1986; 46: 6105–6110.
45. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in
malignant glioma cells by arsenic trioxide. Cancer Res 2003; 63: 2103–2108.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0Unported License. To viewacopyofthis license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)
Anticancer effects of a tellurium compound in mice
R Coriat et al
10
Cell Death and Disease